Preliminary Assessment of Cone Beam CT Guided Percutaneous Cryoablation for CT1A Renal Cell Carcinoma: A Relatively...

To assess the efficacy and safety of cone beam CT guided percutaneous cryoablation (CBCT guided PCA) for the treatment of cT1a renal tumors by evaluating oncological outcomes and postoperative complication risk, in comparison to conventional CTguided PCA and laparoscopic cryoablation (LCA) using long-term follow-up data from a single-center cohort.

A retrospective analysis of 3 cryoablation (CA) techniques was conducted at our institution from December 2006 to February 2023. A total of 77 (32.6%) patients underwent CBCT guided PCA, 34 (14.4%) received CT guided PCA, and 125 (53%) were treated with LCA. Primary outcomes included recurrence-free survival (RFS) and overall complication rate (OCR). RFS was calculated using the Kaplan-Meier method. Univariate and multivariate Cox proportional hazards analyses assessed the impact of specific baseline characteristics on recurrence risk.

19 (8.1%) patients exhibited local disease recurrence during follow-up. Recurrence occurred in 7 (9.1%), 4 (11.8%), and 8 (6.4%) patients in the CBCT guided PCA, CT guided PCA, and LCA group, respectively (P = .549). The overall RFS was 90.1%, 88.2%, and 93.6% for CBCT guided PCA, CT guided PCA, and LCA, respectively. RFS did not differ significantly between the 3 groups (Log-rank for trend: P = .083). No significant difference in overall recurrence (OCR) was observed among the groups (P = .200).

CBCT guided PCA shows higher overall RFS in comparison to CT guided PCA and thereby is an effective and safe alternative for the treatment of small renal masses.